These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29929108)

  • 21. Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications.
    Lopez JC; Pare JR; Blackmer AB; Orth LE
    J Pediatr Health Care; 2022; 36(5):479-488. PubMed ID: 35987555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stiripentol for the treatment of seizures in Dravet syndrome.
    Eschbach K; Knupp KG
    Expert Rev Clin Pharmacol; 2019 May; 12(5):379-388. PubMed ID: 31017478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid.
    McNamara NA; Dang LT; Sturza J; Ziobro JM; Fedak Romanowski EM; Smith GC; Joshi SM; Leber SM; Carlson M; Robertson P; Shellhaas RA
    Epilepsia; 2020 Aug; 61(8):e85-e89. PubMed ID: 32614070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.
    Devinsky O; Nabbout R; Miller I; Laux L; Zolnowska M; Wright S; Roberts C
    Epilepsia; 2019 Feb; 60(2):294-302. PubMed ID: 30582156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome.
    Kaplan JS; Stella N; Catterall WA; Westenbroek RE
    Proc Natl Acad Sci U S A; 2017 Oct; 114(42):11229-11234. PubMed ID: 28973916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [De novo SCN1A gene deletion in therapy-resistant Dravet syndrome].
    Bene J; Hadzsiev K; Komlósi K; Kövesdi E; Mátyás P; Melegh B
    Orv Hetil; 2015 Dec; 156(49):2009-12. PubMed ID: 26614543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel therapeutic options for Dravet and Lennox-Gastaut syndrome.
    Verrotti A; Striano P
    Expert Rev Neurother; 2021 Nov; 21(11):1191-1194. PubMed ID: 33297778
    [No Abstract]   [Full Text] [Related]  

  • 28. Dravet Syndrome: A Review of Current Management.
    Wheless JW; Fulton SP; Mudigoudar BD
    Pediatr Neurol; 2020 Jun; 107():28-40. PubMed ID: 32165031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changing Landscape of Dravet Syndrome Management: An Overview.
    Samanta D
    Neuropediatrics; 2020 Apr; 51(2):135-145. PubMed ID: 32079034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
    Devinsky O; Patel AD; Thiele EA; Wong MH; Appleton R; Harden CL; Greenwood S; Morrison G; Sommerville K;
    Neurology; 2018 Apr; 90(14):e1204-e1211. PubMed ID: 29540584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early-onset epileptic encephalopathy with myoclonic seizures related to 9q33.3-q34.11 deletion involving STXBP1 and SPTAN1 genes.
    Aravindhan A; Shah K; Pak J; Veerapandiyan A
    Epileptic Disord; 2018 Jun; 20(3):214-218. PubMed ID: 29897043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From focal epilepsy to Dravet syndrome--Heterogeneity of the phenotype due to SCN1A mutations of the p.Arg1596 amino acid residue in the Nav1.1 subunit.
    Hoffman-Zacharska D; Szczepanik E; Terczynska I; Goszczanska-Ciuchta A; Zalewska-Miszkurka Z; Tataj R; Bal J
    Neurol Neurochir Pol; 2015; 49(4):258-66. PubMed ID: 26188943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Early diagnosis of Dravet's syndrome: contributions from clinical practice and molecular biology].
    Sanchez-Carpintero R
    Rev Neurol; 2011 Jun; 52(11):681-8. PubMed ID: 21563120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dravet syndrome with favourable cognitive and behavioral development due to a novel SCN1A frameshift mutation.
    Jiang P; Shen J; Yu Y; Jiang L; Xu J; Xu L; Yu H; Gao F
    Clin Neurol Neurosurg; 2016 Jul; 146():144-6. PubMed ID: 27209029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dravet syndrome.
    Lagae L
    Curr Opin Neurol; 2021 Apr; 34(2):213-218. PubMed ID: 33395108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dravet syndrome: new potential genetic modifiers, imaging abnormalities, and ictal findings.
    Gaily E; Anttonen AK; Valanne L; Liukkonen E; Träskelin AL; Polvi A; Lommi M; Muona M; Eriksson K; Lehesjoki AE
    Epilepsia; 2013 Sep; 54(9):1577-85. PubMed ID: 23808377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome.
    Aras LM; Isla J; Mingorance-Le Meur A
    Epilepsy Behav; 2015 Mar; 44():104-9. PubMed ID: 25666511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early clinical features in Dravet syndrome patients with and without SCN1A mutations.
    Petrelli C; Passamonti C; Cesaroni E; Mei D; Guerrini R; Zamponi N; Provinciali L
    Epilepsy Res; 2012 Mar; 99(1-2):21-7. PubMed ID: 22071555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical spectrum of mutations in SCN1A gene: severe myoclonic epilepsy in infancy and related epilepsies.
    Fujiwara T
    Epilepsy Res; 2006 Aug; 70 Suppl 1():S223-30. PubMed ID: 16806826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stiripentol for the treatment of seizures associated with Dravet syndrome.
    Chiron C
    Expert Rev Neurother; 2019 Apr; 19(4):301-310. PubMed ID: 30900478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.